ocadusertib   Click here for help

GtoPdb Ligand ID: 13504

Synonyms: compound I-30 [WO2021046407] | LY-3871801 | LY3871801 | R-552 | R552
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for ocadusertib was obtained from WHO proposed INN list 131 (August 2024). The INN record describes the compound as a serine/threonine kinase inhibitor. A structure match in PubChem suggests that this is the INN for Eli Lilly/Rigel's clinical lead, RIPK1 inhibitor LY3871801, and confirmed by information provided on this pipeline page. Ocadusertib/LY3871801 is one of the structures claimed in patent WO2021046407A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 115.62
Molecular weight 459.5
XLogP 2.63
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)(C#CC1=CC=C2C(=C1)N(C)C(=O)[C@H](CO2)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4)O
Isomeric SMILES CC(C)(C#CC1=CC2=C(C=C1)OC[C@@H](C(=O)N2C)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4)O
InChI InChI=1S/C25H25N5O4/c1-25(2,33)12-11-17-9-10-20-19(13-17)30(3)24(32)18(15-34-20)26-23(31)22-27-21(28-29-22)14-16-7-5-4-6-8-16/h4-10,13,18,33H,14-15H2,1-3H3,(H,26,31)(H,27,28,29)/t18-/m0/s1
InChI Key SQBZJKIINNRUFC-SFHVURJKSA-N
References
1. Chen Y, Yu J, Shaw S, Darwish I, Taylor V, Bhamidipati S, Luo Z, Kolluri K. (2021)
Rip1 inhibitory compounds and methods for making and using the same.
Patent number: WO2021046407A1. Assignee: Rigel Pharmaceuticals, Inc.. Priority date: 04/09/2020. Publication date: 11/03/2021.